ERIC BROADWAY: Open Payments
NPI 1790870905 · STIGLER, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,564 in 97 payments from 9 companies in 2025. Trend: 2023 $2,055 · 2024 $1,787 · 2025 $1,564
Food & beverage: $1,453Education: $111
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 18 | $396 |
| Neurocrine BioSciences, Inc. | 24 | $299 |
| Teva Pharmaceuticals USA, Inc. | 14 | $281 |
| Vanda Pharmaceuticals Inc. | 20 | $220 |
| Alkermes, Inc. | 13 | $214 |
| Supernus Pharmaceuticals, Inc. | 3 | $59 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Janssen Pharmaceuticals, Inc | 1 | $14 |
Products named: COBENFY, INGREZZA, FANAPT, ARISTADA, AUSTEDO XR, Qelbree, CAPLYTA, UZEDY.
Industry payments across OK — which companies pay providers there.
